% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

insidetrack22 3 posts  |  Last Activity: Sep 23, 2015 10:41 PM Member since: Jun 3, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    IMGN is dead money

    by insidetrack22 Sep 21, 2015 11:37 AM
    insidetrack22 insidetrack22 Sep 23, 2015 10:41 PM Flag

    Please speak English

  • insidetrack22 by insidetrack22 Sep 21, 2015 11:37 AM Flag

    (1) IMGN has no inside ownership. This gives you an idea of how much management believes in their own company
    (2) IMGN lives off of royalty which is pennies on the dollar compared to having their own product to sell rather than partnerships
    (3) IMGN sold off its most lucarative revenue Kadcyla stream to put all their eggs into developing one product which has some obstacles to over come before reaching the market, meanwhile IMGN is flleecing investors to stay alive (Don't be surprised if IMGN down the road issue more shares causing dilution)
    (4) As each day goes by, targeted therapy (which is what IMGN does) becomes more irrelvant as immunotherapy takes over the market

    Play IMGN for the roller coaster ride but I don't see putting my retirement money on this stock.

  • insidetrack22 by insidetrack22 Aug 13, 2015 4:48 PM Flag

    Pros: Decent pipeline, Decent partnerships, dynamic oncology sector
    Cons: Lousy financials, low insider ownership, one commercialized product
    Bottom line: FDA approves 20% upside, FDA rejects look out below

10.91+0.25(+2.35%)Oct 9 4:00 PMEDT